請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43845完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 劉興華 | |
| dc.contributor.author | Ti-Jui Chen | en |
| dc.contributor.author | 陳帝瑞 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:30:22Z | - |
| dc.date.available | 2011-09-15 | |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-17 | |
| dc.identifier.citation | Aliev, G., Smith, M. A., Obrenovich, M. E., de la Torre, J. C., & Perry, G. (2003).
Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res, 5(7), 491-504. Basta, G., Schmidt, A. M., & De Caterina, R. (2004). Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res, 63(4), 582-592. Beranek, M., Novakova, D., Rozsival, P., Drsata, J., & Palicka, V. (2006). Glycation and advanced glycation end-products in laboratory experiments in vivo and in vitro. Acta Medica (Hradec Kralove), 49(1), 35-39. Bohlender, J., Franke, S., Sommer, M., & Stein, G. (2005). Advanced glycation end products: a possible link to angiotensin in an animal model. Ann N Y Acad Sci, 1043, 681-684. Bonnardel-Phu, E., Wautier, J. L., & Vicaut, E. (2000). [Advanced glycation end products are involved in microvascular permeability changes observed in microcirculation of diabetic rats in vivo]. J Mal Vasc, 25(2), 122-127. Bro, S., Flyvbjerg, A., Binder, C. J., Bang, C. A., Denner, L., Olgaard, K., et al. (2008). A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis, 201(2), 274-280. Busch, M., Franke, S., Wolf, G., Rohde, R. D., & Stein, G. (2008). Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract, 108(4), c291-297. 49 Cooke, C. L., Brockelsby, J. C., Baker, P. N., & Davidge, S. T. (2003). The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens Pregnancy, 22(2), 173-184. Cuomo, A. V., Virk, M., Petrigliano, F., Morgan, E. F., & Lieberman, J. R. (2009). Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am, 91(5), 1073-1083. Degenhardt, T. P., Fu, M. X., Voss, E., Reiff, K., Neidlein, R., Strein, K., et al. (1999). Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Diabetes Res Clin Pract, 43(2), 81-89. Forbes, J. M., Yee, L. T., Thallas, V., Lassila, M., Candido, R., Jandeleit-Dahm, K. A., et al. (2004). Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes, 53(7), 1813-1823. Hein, G., Wiegand, R., Lehmann, G., Stein, G., & Franke, S. (2003). Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford), 42(10), 1242-1246. Hong, Y. H., Hishikawa, D., Miyahara, H., Tsuzuki, H., Nishimura, Y., Gotoh, C., et al. (2005). Up-regulation of adipogenin, an adipocyte plasma transmembrane protein, during adipogenesis. Mol Cell Biochem, 276(1-2), 133-141. Hurson, C. J., Butler, J. S., Keating, D. T., Murray, D. W., Sadlier, D. M., O'Byrne, J. M., et al. (2007). Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord, 8, 12. Huttunen, H. J., Fages, C., & Rauvala, H. (1999). Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem, 274(28), 19919-19924. Justesen, J., Stenderup, K., Eriksen, E. F., & Kassem, M. (2002). Maintenance of osteoblastic and adipocytic differentiation potential with age and osteoporosis in human marrow stromal cell cultures. Calcif Tissue Int, 71(1), 36-44. 50 Kalea, A. Z., Schmidt, A. M., & Hudson, B. I. (2009). RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond), 116(8), 621-637. Kume, S., Kato, S., Yamagishi, S., Inagaki, Y., Ueda, S., Arima, N., et al. (2005). Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res, 20(9), 1647-1658. Machado, A. P., Pinto, R. S., Moyses, Z. P., Nakandakare, E. R., Quintao, E. C., & Passarelli, M. (2006). Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol, 38(3), 392-403. Matsubara, Y., Endo, T., & Kano, K. (2008). Fatty acids but not dexamethasone are essential inducers for chick adipocyte differentiation in vitro. Comp Biochem Physiol A Mol Integr Physiol. Ostendorp, T., Leclerc, E., Galichet, A., Koch, M., Demling, N., Weigle, B., et al. (2007). Structural and functional insights into RAGE activation by multimeric S100B. EMBO J, 26(16), 3868-3878. Pallottini, V., Martini, C., Cavallini, G., Bergamini, E., Mustard, K. J., Hardie, D. G., et al. (2007). Age-related HMG-CoA reductase deregulation depends on ROS-induced p38 activation. Mech Ageing Dev, 128(11-12), 688-695. Saito, M. (2007). [Role of enzymatic cross-links and non-enzymatic cross-link, advanced glycation end products, as a determinant of bone quality in osteoporosis and diabetes]. Nippon Rinsho, 65 Suppl 9, 209-213. Sakaue, H., & Takashima, Y. (2009). [Adipocyte proliferation and differentiation: molecular aspects and regulatory factors]. Nippon Rinsho, 67(2), 222-227. Valcourt, U., Merle, B., Gineyts, E., Viguet-Carrin, S., Delmas, P. D., & Garnero, P. (2007). Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem, 282(8), 5691-5703. Viguet-Carrin, S., Roux, J. P., Arlot, M. E., Merabet, Z., Leeming, D. J., Byrjalsen, I., et al. (2006). Contribution of the advanced glycation end product pentosidine 51 and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone, 39(5), 1073-1079. Vlassara, H., & Palace, M. R. (2002). Diabetes and advanced glycation endproducts. J Intern Med, 251(2), 87-101. Wendt, T., Bucciarelli, L., Qu, W., Lu, Y., Yan, S. F., Stern, D. M., et al. (2002). Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep, 4(3), 228-237. Xie, J., Reverdatto, S., Frolov, A., Hoffmann, R., Burz, D. S., & Shekhtman, A. (2008). Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem, 283(40), 27255-27269. Yamagishi, S., Nakamura, K., & Inoue, H. (2005). Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses, 65(6), 1013-1015. Zeballos, G. A., Bernstein, R. D., Thompson, C. I., Forfia, P. R., Seyedi, N., Shen, W., et al. (1995). Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation, 91(12), 2982-2988. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43845 | - |
| dc.description.abstract | 羧甲基離胺酸(CML)為最終糖化產物(AGEs)的主要成分，在糖尿病以及老化之
病人的血管以及組織中，常常發現有累積的現象而導致其他併發症，如:骨質疏 鬆症。先前研究發現AGEs 可調控骨髓間質幹細胞的分化作用，包括脂肪細胞 分化以及造骨細胞分化。但是至今其分子機制尚未了解。 因此本篇主要探討羧甲基離胺酸對於間質幹細胞分化成造骨細胞以及脂肪細 胞的影響。首先我們先利用MTT 試驗來選定不造成細胞死亡的使用劑量: 25μ g/ml，發現在此劑量下能夠有效抑制造骨細胞分化主要是透過促進RAGE、 iNOS、,NO 產生及表現或是抑制PP38、ALP、BMP-2 及OCN 來抑制骨生成。胺 基胍(AG)以及RAGE 接受器之抗體不但能有效回復抑制骨生成也能回復PP38 等 分化訊號表現。而SNP 加入後則可以抑制PP38 以及ALP 活性，證明NO 在此扮 演重要的角色。接下來我們發現羧甲基離胺酸在此無法增加NO 但是卻能夠造成 細胞內ROS 大量產生，並且能夠有效抑制脂肪細胞分化主要是透過抑制ERK 磷 酸化以及PPAR-γ表現量的訊息路徑。加入NAC 以及RAGE 接受器抗體後則可 以明顯回復抑制情形。表示羧甲基離胺酸的作用是透過ROS 的產生並且扮演著 重要的角色，進而影響了細胞分化的相關蛋白質訊號表現。 在動物實驗方面，我們發現STZ 誘導糖尿病之小鼠組別的血液樣本中AGEs 有明顯增高，而頭部以及脛骨之骨密度以及骨質量皆有下降之趨勢。而經由餵食 AG 飲水(20-25mg/day)的組別不但骨密度及骨質量皆有輕微緩解之外，血液中 AGEs 含量以及小鼠體重皆有些微回復。 綜合以上結果，羧甲基離胺酸對於小鼠間質幹細胞之脂肪細胞分化以及造骨細 胞分化作用上扮演著重要調節之角色。未來的研究，對於間質幹細胞的分化調控 的詳細機制，更值得進一步釐清。 | zh_TW |
| dc.description.abstract | N-carboxymethyllysine (CML), the major component of advanced glycation end
products (AGEs), accumulates in vessels and tissues of aging and diabetic patients. In the recent studies, AGEs can regulate mesenchymal stem cell differentiation, But the molecular mechanisms remain unknown. The present studies, CML were used to investigate the effect on osteogenesis and adipogenesis of bone marrow mesenchymal stem cells. The testing doses used in this study were without cytotoxicity. We found that CML( 25μg/ml ) inhibited bone formation via increasing the expression of RAGE(AGEs receptor) and iNOS, as well as NO production, but decreasing the expression of pP38, ALP, BMP-2, and OCN. Aminoguanidine (AG) and RAGE antibody can reverse not only the inhibited effect of CML in osteogenesis but also the signaling pathway. SNP (NO donor) treatment also can inhibit the P38 and ALP activity, suggesting that Nitrite oxide (NO) plays an important role in osteogenesis. Moreover, we also found that 25μg/ml CML can inhibit adipogenesis by downregulating the ERK phosphorylation and PPAR-γexpression. The reactive oxygen species (ROS) was generated after CML treatment. Then, NAC and RAGE antibody can reverse the expression of pERK and PPAR-γand adipogenesis, suggesting that ROS plays an important role in adipogenesis. In vivo study, we examined the elevating of AGEs in serum of STZ-induced diabetic mice. The BMD and BMC of head and tibia are decreased, but AG could partially regulate BMD of STZ-induced diabetic mice. The AGEs amount and the body weight also could be regulated by Aminoguanidine(20-25mg/day). In conclusion, we thought that CML plays an important role in osteogenesis and adipogenesis of MSCs. In the future, the detail mechanism of the CML effect on MSCs differentiation and the relation with osteoporosis are still valuably investigated. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:30:22Z (GMT). No. of bitstreams: 1 ntu-98-R96447005-1.pdf: 2121041 bytes, checksum: edff2039e296b9abb983a872d8d9a6fe (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 中文摘要-------------------------------------------------P1
英文摘要------------------------------------------------ P2 第一章 序論------------------------------------------P3-P16 第二章研究目的------------------------------------------P17 第三章 材料與方法-----------------------------------P18-P31 第四章 實驗結果-------------------------------------P32-P42 第五章 結果討論------------------------------------ P43-P47 第六章 參考文獻-------------------------------------P48-P51 附圖------------------------------------------------P52-P77 | |
| dc.language.iso | zh-TW | |
| dc.subject | 糖尿病 | zh_TW |
| dc.subject | 脂肪細胞 | zh_TW |
| dc.subject | 造骨細胞 | zh_TW |
| dc.subject | 骨質疏鬆症 | zh_TW |
| dc.subject | osteoblast | en |
| dc.subject | osteoporosis | en |
| dc.subject | adipocyte | en |
| dc.subject | diabetes | en |
| dc.title | N-羧甲基離胺酸對於造骨細胞與脂肪細胞分化之作用 | zh_TW |
| dc.title | Effects of N-carboxymethyllysine on Osteogenesis and Adipogenesis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蕭水銀,楊榮森 | |
| dc.subject.keyword | 脂肪細胞,造骨細胞,糖尿病,骨質疏鬆症, | zh_TW |
| dc.subject.keyword | adipocyte,osteoblast,diabetes,osteoporosis, | en |
| dc.relation.page | 77 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 毒理學研究所 | zh_TW |
| 顯示於系所單位： | 毒理學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 2.07 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。